Hexarelin vs sermorelin: how these two GHRPs differ

Last updated 2026-07-24

What are hexarelin and sermorelin, and how are they different classes of peptide?

Sermorelin is a 29-amino acid fragment of growth hormone releasing hormone (GHRH), the natural hypothalamic signal that tells the pituitary to make and release growth hormone. It works on the GHRH receptor, the same receptor your body already uses. The FDA approved a sermorelin acetate product, branded Geref, back in 1997 for diagnosing and treating growth hormone deficiency in children ^[1]. Geref was discontinued by its manufacturer for business reasons, not pulled for a safety problem. That regulatory paper trail is unusual in the peptide world, where most compounds have never been through FDA review at all. Hexarelin is a synthetic hexapeptide (six amino acids) that belongs to a completely different family: growth hormone releasing peptides (GHRPs), sometimes called ghrelin mimetics. It acts on the ghrelin receptor (GHS-R1a), not the GHRH receptor. That single mechanistic difference explains almost everything else in this comparison, from how strong the GH pulse is to what else gets released alongside it. Because they hit different receptors, sermorelin and hexarelin are sometimes discussed as a stacking pair in bodybuilding and anti-aging forums, on the theory that GHRH plus a GHRP produces more GH than either alone. There is pharmacological logic to that. Studies going back decades show GHRH and GHRP-family peptides synergize on GH release ^[2]. But neither hexarelin nor any GHRP is FDA-approved for human use, and combination use has no clinical trial safety data behind it. For a full rundown of what sermorelin does on its own, see sermorelin.

How much stronger is hexarelin's GH release compared to sermorelin's?

Hexarelin is dramatically more potent per microgram than sermorelin. Early pharmacology work found hexarelin to be one of the most potent GH secretagogues identified, producing GH spikes several times higher than GHRH alone in human trials ^[3]. Sermorelin's job, by contrast, is to nudge the pituitary toward its own natural pulse, not override it. That difference in magnitude is the whole tradeoff. Sermorelin's GH release is capped by how much GH the pituitary is physiologically willing to make and by feedback inhibition from somatostatin, the body's natural brake. Hexarelin partially bypasses that brake. That's exactly why it produces a bigger number on a blood test, and exactly why it comes with more side-effect baggage.

Does hexarelin raise cortisol and prolactin more than sermorelin?

Yes, and this is one of the clearest points of separation between the two. Because hexarelin acts on the ghrelin receptor pathway, it isn't purely selective for GH. Clinical studies of hexarelin in humans documented significant increases in cortisol and prolactin alongside the GH spike ^[3], effects that are not typical of GHRH-based peptides like sermorelin at studied doses. Cortisol and prolactin aren't inert numbers. Chronically elevated cortisol is linked to worse sleep, appetite changes, and metabolic strain, and elevated prolactin can affect libido and menstrual cycles. This is a real reason clinicians who work with GHRH analogs tend to be more cautious recommending GHRP-class peptides like hexarelin for anything other than short, monitored research contexts. Sermorelin, working through the more physiologic GHRH pathway, is not associated with meaningful cortisol or prolactin elevation in the studies and prescribing history behind Geref ^[1]. That's a meaningful safety margin difference, more than a marketing point.

Does the body build tolerance to hexarelin faster than to sermorelin?

Desensitization is a documented issue with hexarelin specifically. Research on repeated hexarelin dosing found that its GH-releasing effect diminishes with continued use, a pattern consistent with receptor downregulation on the ghrelin receptor pathway ^[4]. In practice, that means the strong first-week response people report with hexarelin often fades. Sermorelin's tolerance picture looks different, largely because it works with, not around, the body's own pulsatile feedback loop. The Geref-era clinical data and later real-world prescribing for adult GH support did not describe the same rapid loss of effect. That doesn't mean sermorelin works forever without any adaptation. It means the drop-off isn't as steep or fast as what's reported with hexarelin. If you're trying to understand what a realistic multi-month sermorelin course looks like, the sermorelin dosage chart breaks down typical titration schedules.

Are there cardiac safety concerns unique to hexarelin?

Hexarelin has actually been studied for potential cardioprotective effects in animal models, which sounds reassuring but is more complicated than it looks. Some experimental work in rodents explored hexarelin's action on cardiac ghrelin receptors and possible protective effects after cardiac injury ^[5]. But that line of research was conducted in disease models to study a specific mechanism, not as evidence that hexarelin is safe for casual human use. Ghrelin receptor activation touches cardiovascular signaling in ways GHRH analogs generally don't. That's part of why hexarelin's off-label human use carries more uncertainty than sermorelin's. Nobody has run large, long-term human safety trials on hexarelin at the doses people are using informally, and the compound has never gone through an FDA approval process at all, so there's no post-marketing surveillance data (the kind the FDA collects for approved drugs) to lean on either. Sermorelin, by comparison, has an FDA approval and prescribing history to point to, even though the branded product (Geref) is no longer commercially available ^[1].

How does dosing actually compare between hexarelin and sermorelin?

Sermorelin is typically dosed in the range compounding pharmacies and prescribers use for adult GH support, generally a nightly subcutaneous injection timed before bed to align with the body's natural nocturnal GH pulse. The original Geref labeling for pediatric use specified weight-based dosing under physician supervision ^[1], and adult off-label protocols today are lower and more conservative, individualized by a prescriber. For a walkthrough of how those doses are typically calculated by weight and goal, see the sermorelin dosage calculator. Hexarelin dosing in the research literature has generally used single test doses in the low microgram-per-kilogram range to measure acute GH response ^[3], not the kind of nightly chronic dosing schedule sermorelin uses. There is no FDA-reviewed, standardized human dosing protocol for hexarelin, because it has never been approved for any human indication. Anyone using it outside a research study is working from forum protocols and anecdote, not a package insert. That's a genuine and underappreciated difference. Sermorelin dosing has a documented history to reference. Hexarelin dosing does not.

Which one has better long-term human safety data?

Sermorelin, by a wide margin. It went through FDA review for Geref in 1997 ^[1], which means real toxicology and clinical trial data exists in the public record, even though the specific branded product was later discontinued for commercial, not safety, reasons. That gives prescribers and researchers a paper trail to check. Hexarelin has never been FDA-approved for any human use. What exists is a set of smaller academic studies, mostly from the 1990s and 2000s, looking at acute GH, cortisol, and prolactin responses, plus some animal-model cardiac research ^[3][5]. That's useful science, but it's not the same thing as a completed, chronic-use human safety file. For a full picture of what's known and not known about sermorelin's safety over months and years of use, the sermorelin long-term side effects page is the place to start.

Is hexarelin legal and is it sold the same way as sermorelin?

Neither peptide is FDA-approved as a currently marketed drug in the US, but they sit in different regulatory positions. Sermorelin has FDA-approved history (Geref) and is available today through compounding pharmacies with a prescription, under the framework Congress set out for pharmacy compounding ^[6]. Hexarelin has no FDA approval history at all and is generally sold as a "research chemical," not intended for human use, which is a legal label, not a safety endorsement. That research-chemical labeling matters. It means hexarelin sold online typically has no pharmacy oversight, no prescriber verifying purity or dose, and no chain of accountability if the product is mislabeled or contaminated. If you're weighing where to source sermorelin through a legitimate provider-reviewed pathway instead of gray-market channels, sermorelin peptide near me and sermorelin reviews cover what a legitimate process looks like.

How does sermorelin compare to HGH itself, more than to hexarelin?

This is probably the more important question for most readers, so it's worth answering directly. Sermorelin is not a substitute for HGH (recombinant human growth hormone) in every situation, and being honest about that matters more than making sermorelin sound good. HGH injections put the actual hormone directly into your bloodstream. That produces a bigger, more predictable rise in GH and downstream IGF-1 than sermorelin can, because it skips the pituitary step entirely. That's why HGH remains the standard approach for confirmed growth hormone deficiency, monitored with blood testing under an endocrinologist ^[7]. Sermorelin works upstream: it stimulates your own pituitary to release GH, so its ceiling is limited by how much functional pituitary tissue you have and by your body's own feedback loops. If your pituitary is significantly damaged or non-functional, sermorelin simply won't work as well as direct HGH replacement. That's a real limitation, not a minor caveat. Where sermorelin has an edge is in its more physiologic release pattern (pulsatile, aligned with sleep) and its longer regulatory track record for mild-to-moderate cases and off-label adult use, plus a generally milder side effect profile than high-dose HGH, which carries its own well-documented risks like fluid retention, joint pain, and insulin resistance at supraphysiologic doses ^[7]. Neither sermorelin nor hexarelin is approved or evidenced for anti-aging, athletic performance, or fat loss claims, regardless of what marketing around either compound suggests.

Which peptide would a cautious prescriber recommend, and why?

Between these two specifically, sermorelin is the more defensible choice for anyone talking with a prescriber about growth hormone support. It has an FDA approval history, a milder side effect profile, no documented cortisol or prolactin problem, and a dosing structure with real precedent behind it. Hexarelin's strength, its outsized GH punch, is also its liability. The same ghrelin-receptor mechanism that makes it powerful also brings cortisol and prolactin along for the ride, and its effect fades faster with repeated use. Add in the complete absence of FDA review and the research-chemical sourcing situation, and hexarelin looks like a compound better suited to lab research than to a home injection routine. That said, sermorelin is not a magic upgrade over HGH either. If you have documented, lab-confirmed GH deficiency, HGH replacement under an endocrinologist is still the established medical standard ^[7]. Sermorelin's honest lane is adults with mild age-related decline in GH pulsatility who want a gentler, prescriber-supervised nudge to their own system, worked out through provider-reviewed protocols and filled through a licensed pharmacy, not gray-market vials with no chain of custody.

Frequently asked questions

Is hexarelin stronger than sermorelin?

Yes, in terms of raw GH release per dose, hexarelin produces a much larger GH spike than sermorelin. Human studies found hexarelin among the most potent GH secretagogues tested ^[3]. But stronger isn't automatically better: hexarelin also raises cortisol and prolactin more, and its effect fades faster with repeated dosing than sermorelin's.

Can you stack hexarelin and sermorelin together?

Pharmacologically, GHRH-class peptides like sermorelin and GHRP-class peptides like hexarelin can synergize on GH release ^[2], which is why some protocols combine them. But no clinical trial has established a safe, standardized combined dosing schedule for humans, and hexarelin carries its own unresolved cortisol and prolactin concerns. Talk to a prescriber before combining any peptides.

Is hexarelin FDA-approved?

No. Hexarelin has never gone through FDA approval for any human indication and is generally sold as a research chemical not intended for human use. Sermorelin, by contrast, was FDA-approved as Geref in 1997 for pediatric growth hormone deficiency before being discontinued commercially for business reasons ^[1].

Why was Geref (branded sermorelin) discontinued?

Geref was discontinued by its manufacturer for commercial reasons, not because of a safety recall or FDA action against it. The FDA approval record for sermorelin acetate remains part of the public regulatory history ^[1], which is part of why sermorelin has more documented safety background than most peptides sold today.

Does hexarelin raise prolactin and cortisol?

Yes. Clinical studies of hexarelin documented meaningful increases in both cortisol and prolactin alongside its GH-releasing effect ^[3], a pattern tied to its action on the ghrelin receptor pathway. Sermorelin, working through the GHRH receptor, does not show this same effect in its clinical history.

Does sermorelin or hexarelin work better for anti-aging?

Neither has solid evidence supporting anti-aging claims. Both are studied primarily for their acute effects on GH secretion, not for reversing aging markers. Any anti-aging marketing around either compound is running ahead of the actual clinical evidence, and a cautious prescriber will not frame either one that way.

Is sermorelin the same as HGH?

No. Sermorelin stimulates your pituitary gland to make and release your own growth hormone. HGH (recombinant human growth hormone) is the hormone itself, injected directly. HGH produces a larger, more direct effect and remains the standard treatment for confirmed GH deficiency ^[7], while sermorelin is a gentler, upstream approach with a smaller ceiling.

Which has more side effects, hexarelin or sermorelin?

Hexarelin's side effect profile is more concerning based on available studies, largely due to its cortisol and prolactin elevation and receptor desensitization with repeated use ^[3][4]. Sermorelin's documented side effects, drawn from its FDA-reviewed Geref history, are generally limited to injection site reactions and flushing at studied doses ^[1].

Can you buy hexarelin legally in the US?

Hexarelin is generally sold labeled as a research chemical, not for human consumption, which sidesteps FDA drug approval requirements but also means no pharmacy oversight, no verified dosing, and no prescriber accountability. Sermorelin, by contrast, can be obtained through licensed compounding pharmacies with a prescription under the compounding framework set out in federal law ^[6].

How is sermorelin typically dosed compared to hexarelin?

Sermorelin is usually dosed as a nightly subcutaneous injection, individualized by a prescriber and often based on body weight, timed to align with natural nocturnal GH pulses. Hexarelin in the research literature has mostly been tested as single acute doses in micrograms per kilogram ^[3], with no established chronic human dosing protocol.

Does the body stop responding to hexarelin over time?

Yes, this is documented. Studies on repeated hexarelin administration found the GH-releasing response diminishes with continued use, consistent with receptor downregulation on the ghrelin receptor ^[4]. Sermorelin's documented use history does not describe this same rapid drop-off, likely because it works with the body's natural feedback loop rather than around it.

Is hexarelin used for anything besides GH release?

Some animal studies have explored hexarelin's ghrelin receptor activity in cardiac tissue for potential cardioprotective effects after injury ^[5]. This is early-stage mechanistic research in disease models, not evidence supporting general human use, and it hasn't led to any approved human indication for hexarelin.

Sources

1. U.S. Food and Drug Administration, Drugs@FDA record for Geref (sermorelin acetate), NDA 019676, approved 1997: Sermorelin acetate was FDA-approved as Geref in 1997 and later discontinued commercially, not for safety reasons
2. Bowers CY, et al., "Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone," Journal of Clinical Endocrinology & Metabolism, 1990, PMID 2394734: GHRH and GHRP-class peptides can synergize to increase GH release when combined
3. Ghigo E, et al., "Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in humans," Journal of Clinical Endocrinology & Metabolism, 1994, PMID 8077321: Hexarelin produces large GH spikes along with significant cortisol and prolactin increases in human trials
4. Ghigo E, et al., study on repeated hexarelin administration and GH response desensitization, Journal of Endocrinological Investigation, PMID 9075343: Repeated hexarelin dosing shows diminished GH-releasing effect over time, consistent with receptor desensitization
5. Bathgate-Siryk A, et al., hexarelin and cardiac ghrelin receptor signaling research, Journal of Molecular and Cellular Cardiology, PMID 24565571: Animal studies have explored hexarelin's ghrelin receptor activity for potential cardioprotective effects
6. 21 U.S.C. 353a, Pharmacy compounding, via U.S. Government Publishing Office: Compounded drug products, including sermorelin, are regulated under a distinct federal statutory framework rather than standard new drug approval
7. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), growth hormone deficiency in adults: HGH replacement remains the established medical standard for confirmed growth hormone deficiency and carries known risks at high doses
8. MedlinePlus (National Library of Medicine), Sermorelin injection drug information: Sermorelin's documented clinical side effects include injection site reactions and flushing at studied doses